BofA lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $29 from $31 and keeps a Neutral rating on the shares. The firm maintains its FY26 Daybue sales estimate of $470M, given that the recent $460M-$490M sales guidance did not assume an EU approval, but cites other model changes for its revised target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Balancing EU Setback and Pipeline Optionality: Justifying a Hold on ACADIA
- ACADIA Pharmaceuticals Charts Growth Path After Record Year
- Acadia Pharmaceuticals price target lowered to $33 from $36 at Citi
- Acadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen
- Acadia Pharmaceuticals price target raised to $26 from $25 at Morgan Stanley